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Abstract
Objective—To report the clinical, radiological, and immunological association of demyelinating
disorders with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
Methods—Clinical and radiological analysis of a cohort of 691 patients with anti-NMDAR
encephalitis. Determination of antibodies to NMDAR, aquaporin-4 (AQP4) and myelin
Address correspondence to: Josep Dalmau, MD, PhD, Service of Neurology, IDIBAPSHospital Clínic, University of Barcelona,




Ann Neurol. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:






















oligodendrocyte glycoprotein (MOG) was performed using brain immunohistochemistry and cell-
based assays.
Results—Twenty-three of 691 patients with anti-NMDAR encephalitis had prominent MRI
and/or clinical features of demyelination. Group 1 included 12 patients in whom anti-NMDAR
encephalitis was preceded or followed by independent episodes of NMO-spectrum disorder (5
cases, 4 anti-AQP4-positive), or brainstem or multifocal demyelinating syndromes (7 cases, all
anti-MOG-positive). Group 2 included 11 patients in whom anti-NMDAR encephalitis occurred
simultaneously with MRI and symptoms compatible with demyelination (5 AQ4-positive, 2
MOG-positive). Group 3 (136 controls) included 50 randomly selected patients with typical anti-
NMDAR encephalitis, 56 with NMO, and 30 with multiple sclerosis: NMDAR-antibodies were
detected only in the 50 anti-NMDAR patients, MOG-antibodies in 3/50 anti-NMDAR and 1/56
NMO patients, and AQP4-antibodies in 48/56 NMO and 1/50 anti-NMDAR patients (p<0.0001
for all comparisons with Groups 1 and 2). Most patients improved with immunotherapy, but
compared with anti-NMDAR encephalitis the demyelinating episodes required more intensive
therapy and resulted in more residual deficits. Only 1/23 NMDAR patients with signs of
demyelination had ovarian teratoma compared with 18/50 anti-NMDAR controls (p=0.011)
Interpretation—Patients with anti-NMDAR encephalitis may develop concurrent or separate
episodes of demyelinating disorders, and conversely patients with NMO or demyelinating
disorders with atypical symptoms (e.g., dyskinesias, psychosis) may have anti-NMDAR
encephalitis.
Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe autoimmune
disorder that occurs in association with IgG antibodies against the GluN1 subunit of the
NMDAR.1 The pathogenic effects of the antibodies have been demonstrated at the cellular
and synaptic levels using in vitro and in vivo models.2,3 Despite the severity of symptoms,
only 35% of the patients have abnormal brain MRI at disease onset,4 increasing to 50%
when the entire course of the disease is considered.1 The abnormalities identified on routine
MRI studies are often mild, transient and non-specific, preferentially seen in FLAIR
sequences, usually involving cortical and subcortical regions of the brain and hippocampus,
but sometimes affecting the basal ganglia. Over the last five years we have identified
patients with anti-NMDAR encephalitis with additional symptoms or episodes suggesting a
demyelinating disorder. This finding is in line with a few case reports of anti-NMDAR
encephalitis associated with acute demyelinating encephalomyelitis (ADEM), myelitis, or
neuromyelitis optica (NMO) without aquaporin-4 (AQP4) antibodies.5–7 It is well
established that AQP4 antibodies are useful to differentiate NMO and NMO-spectrum
disorder (NMOSD) with spatially limited phenotypes such as optic neuritis (ON) or
longitudinally extensive transverse myelitis (LETM) from other autoimmune disorders of
the CNS.8–10 Some patients with NMO without AQP4 antibodies have serum antibodies to
myelin oligodendrocyte glycoprotein (MOG),11,12 and these antibodies have been reported
in children with ADEM.12–16 The recognition that anti-NMDAR encephalitis and a
demyelinating disorder may occur in the same patient is important because treatment and
outcome vary for each disorder, and we suspect that these patients may be misdiagnosed.
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We report here 23 patients with these overlapping syndromes, focusing on the clinical, MRI
and serological (NMDAR, AQP4, MOG) findings, as well as the frequency of these
associations, the responses to treatment, and the long-term outcome.
Methods
Patients
Patients were identified form a cohort of 691 cases with anti-NMDAR encephalitis, whose
serum and CSF samples were sent to the hospitals of the University of Pennsylvania and
University of Barcelona. The diagnosis of anti-NMDAR encephalitis was based on the
presence of symptoms of encephalopathy and antibodies in serum and/or CSF against the
NMDAR confirmed with both rat brain immunohistochemistry and a cell-based assay of
cells expressing GluN1, as reported.17 Criteria for the selection of patients with
demyelinating features included, (1) anti-NMDAR encephalitis, (2) clinical and/or MRI
findings compatible with demyelinating disorders, such as optic neuritis, myelitis, prominent
brainstem dysfunction, and/or (3) T2/FLAIR multifocal, infratentorial or extensive
abnormalities suggesting involvement of the white matter. In all patients the episodes of
demyelination were scored as compatible with NMO or NMOSD as per the revised
Wingerchuk9 and Sellner criteria.8 The presentation of these symptoms and/or MRI features
of demyelination in relation to the time of development of anti-NMDAR encephalitis led us
to consider two groups of patients, 1) those in whom the clinical and/or MRI features of
demyelination occurred as episodes separate from anti-NMDAR encephalitis, and 2) those
in whom the clinical and/or MRI features of demyelination occurred simultaneously with
typical anti-NMDAR encephalitis.
Clinical and MRI data were obtained by the authors or treating physicians at symptom onset
and at different time points during the course of the disease, as reported.4 In addition to the
two indicated groups of patients, which are the focus of the manuscript, three additional
groups were used as controls for antibody studies: 50 patients with anti-NMDAR
encephalitis randomly selected among the indicated 691 cases by use of a random integer
generator (http://www.random.org/integers/), 56 patients with definite NMO (48 with AQP4
antibodies), and 30 patients with multiple sclerosis (MS).
Informed consent was obtained from patients or patients' representatives. Studies were
approved by the institutional review boards of the University of Pennsylvania and the
University of Barcelona.
Antibody studies
Determination of antibodies against NMDAR was performed using both
immunohistochemistry with rat brain and a cell-based assay.1,17 Analysis of antibodies to
AQP4 was performed with both immunohistochemistry with rat brain and a cell based
assay,18 and antibodies to MOG with a cell based assay (see below).12
Immunohistochemistry with rat brain—Non-perfused rat brains were fixed in 4%
paraformaldehyde (PFA) for 1h, cryoprotected with 40% sucrose for 24h, and snap frozen in
chilled isopentane. Seven micron thick sections were then incubated with 0.3% hydrogen
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peroxide for 20 minutes, with 10% goat serum in PBS for 1h, and then labeled with patient's
or control sample (serum: 1:200; CSF: 1:2) at 4°C overnight. The next day, sections were
labeled with the appropriate secondary antibody (1:2000) for 2h at room temperature and
visualized with an avidin-biotin-peroxidase method (Vector lab).
Cell-based assays: The CBA for AQP4 was performed with HEK293 cells transfected with
the M23 isoform of AQP4 (the clone was a gift from Dr. R. Marignier).19 Twenty-four
hours after transfection, live cells were incubated at room temperature with centrifuged
patient's or control samples (serum: 1:20, CSF: 1:2; diluted in DMEM with 1% BSA) for 30
minutes, fixed with 1% PFA for 10 minutes and permeabilized with 0.3% Triton X-100.
HEK cells were then immunolabeled with a rabbit polyclonal anti-AQP4 antibody (1:500;
Sigma-Aldrich) for 1h at room temperature, followed by the corresponding Alexa Fluor 488
and 594 secondary antibodies against human and rabbit IgGs (1:1000).
The CBA for MOG was performed with HEK293 cells transfected with the full-length MOG
C-terminally fused to EGFP (the clone was a gift from Dr. M. Reindl).12 Twenty-four hours
after transfection, live cells were incubated at 37°C with patient's or control samples for 30
minutes, fixed with 4% PFA for 10 minutes and permeabilized with 0.3% Triton X-100.
HEK cells were then immunolabeled with an Alexa Fluor 594 secondary antibody against
human IgG (1:1000). We used a high-titer cut-off (≥1:160) for serum to consider a patient as
MOG-antibody positive as described before,12,20 while we used a minimum dilution of 1:2
for CSF.
Statistical analysis
Frequencies of characteristics within the different patient groups were compared by the
Fisher-Freeman-Halton extension of the Fisher Exact test for dichotomous outcomes or by
the Kruskal-Wallis test for continuous variables.
Results
Twenty-three patients (3.3%) with anti-NMDAR encephalitis and clinical and/or MRI
features of demyelination were identified. The distribution of cases by clinical, MRI, and
serological findings, and the temporal relationship between anti-NMDAR encephalitis and
the clinical/MRI features of demyelination (Demyelination Syndrome Episode, or DSE) are
summarized in Figure 1.
Group 1 (“NMDAR-DSE”, Figure 1, Table 1) includes 12 patients who developed anti-
NMDAR encephalitis preceded or followed by one or more DSE; in all patients the
diagnosis was made by the time they developed the symptoms. Four of these patients had
AQP4 antibodies (Figure 2 A, C) fulfilling criteria for NMOSD or definite NMO, and one
had definite NMO without AQP4 antibodies.8,9 All patients with AQP4 antibodies had the
episode of NMOSD before experiencing anti-NMDAR encephalitis (11–80 months), while
the patient with NMO without AQP4 antibodies developed the first episode of NMO one
month after full recovery from anti-NMDAR encephalitis. The other seven patients,
including three with a brainstem syndrome and four with a multifocal demyelinating
episode, all had MOG antibodies (Figure 2 B, C). In four of these seven patients anti-
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NMDAR encephalitis occurred 3–36 months before the DSE and in the other three 22–96
months after. The episodes of anti-NMDAR encephalitis of these patients were similar to
those of patients with typical anti-NMDAR encephalitis without overlapping demyelinating
features (Figure 3A). An example of the course of symptoms in a patient with NMDAR and
MOG antibodies is shown in Figure 3B. All 12 patients had abnormal MRI findings
(examples provided in Figure 4); eight had infratentorial or spinal cord abnormalities
(p<0.0001, compared to NMDAR-controls, Table 2). None of these patients had a tumor
(p=0.011), and their clinical picture was milder than that of patients in the anti-NMDAR
control group (p=0.001). A 37 year-old woman (case 3) developed acetylcholine receptor
antibody-positive myasthenia gravis for which she underwent elective thymectomy; seven
years later she developed NMOSD, and 30 months thereafter presented with anti-NMDAR
encephalitis.
In 10 patients the symptoms related to anti-NMDAR encephalitis responded to first-line
immunotherapies (steroids, IVIg, plasma exchange); one patient was recently started on
rituximab and has shown progressive improvement, and one patient died (Table 1). As far as
the symptoms related to DSE are concerned, 11/12 patients showed partial improvement,
requiring more intensive treatment than that used for anti-NMDAR encephalitis (Table 1).
Seven out of 12 patients needed second-line immunotherapy. Eventually, 9 of 12 patients
had good outcome (mRS 0–2) although only two had complete recovery. The other three
patients had poor outcome, and in general the residual deficits of the demyelinating event
predominated over the mild deficits of anti-NMDAR encephalitis.
Group 2 (“NMDAR + clinical/MRI features of demyelination”, Figure 1, Table 3) includes
11 patients with anti-NMDAR encephalitis occurring simultaneously with extensive FLAIR-
T2 abnormalities which in five cases involved the infratentorial region or spinal cord
(examples provided in Figure 5). None of these 11 patients developed separate episodes of
DSE. Two patients had relapses of anti-NMDAR encephalitis that were typical and identical
to (but milder than) the initial episode of anti-NMDAR encephalitis. Five patients had AQP4
antibodies (Table 3); three of them had atypical symptoms during the episode of encephalitis
consisting of bilateral facial and bulbar palsy in one, ataxia and hemiparesis in another, and
ataxic gait in the third. The other two patients with AQP4 antibodies had no symptoms that
would suggest NMOSD. Of the six AQP4 antibody-negative patients, two had MOG
antibodies and four did not (Table 3). The two patients with MOG antibodies had
infratentorial MRI abnormalities and unusual symptoms in addition to a syndrome highly
suggestive of anti-NMDAR encephalitis. Among the four patients without MOG antibodies,
three had some unusual clinical features shown in Table 3.
Overall, compared with patients of group 1, in whom the episodes of anti-NMDAR were
separated in time from the DSE, and with patients of the control group with anti-NMDAR
encephalitis (without history of demyelinating episodes), those of group 2 were more likely
to have prominent infratentorial or spinal cord symptoms (p=0.002, Figure 3A). Five of 10
patients (1 is lost to follow-up) required second-line immunotherapy after initial
immunotherapy. Overall, seven of 10 had good outcome. Two of the three patients with poor
outcome had AQP4 antibodies in addition to NMDAR antibodies.
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Control groups (Figure 1). Among the 50 random patients with typical anti-NMDAR
encephalitis, only one (2%) had AQP4 antibodies. Therefore, the frequency of AQP4
antibodies in this group of patients was significantly lower than that found in Groups 1 and 2
(p<0.0001, Table 2). The patient with AQP4 antibodies was a 46-year old woman who
presented with dysarthria but otherwise had a clinical picture typical of anti-NMDAR
encephalitis, including behavioral problems, confusion, memory deficits, akinetic mutism,
orofacial dyskinesias, hyperthermia and central hypoventilation. The brain MRI was normal
(spinal cord not examined), and she did not develop symptoms of demyelinating events in
the 37 month follow-up. The clinical features of the other 49 patients were typical of anti-
NMDAR encephalitis and comparable to those published.4 Three of these 49 patients had
low-titer MOG antibodies, demonstrating that the frequency of these antibodies in this group
of patients was also significantly lower than that found in Groups 1 and 2 (p<0.0001, clinical
details in Table 4).
Among the 56 control patients with NMO (48 with AQP4 antibodies), only one had MOG
antibodies (without AQP4 antibodies), and none had NMDAR antibodies (clinical details in
Table 4). None of the 30 patients with multiple sclerosis had NMDAR, AQP4, or MOG
antibodies.
Discussion
This study provides several novel findings that are important for the recognition, treatment,
and prognosis of a subgroup of patients with anti-NMDAR encephalitis occurring
simultaneously or sequentially with clinical and/or MRI features of demyelinating disorders.
In these patients, immunological studies often show independent but co-existing immune
mechanisms underlying each of these disorders, such as AQP4 or MOG antibodies in
association with NMDAR antibodies. Moreover, the data on outcome demonstrate that the
demyelinating episodes are more difficult to treat than anti-NMDAR encephalitis and often
result in more residual deficits, emphasizing the importance of prompt diagnosis and
treatment.
The frequency of sequential or coexisting anti-NMDAR encephalitis and demyelinating
disorders is unknown. Most patients with anti-NMDAR encephalitis have normal, mild, or
transient MRI abnormalities. In contrast, the patients included here had extensive or
multifocal T2-FLAIR abnormalities, representing 3.3% of cases in a cohort of 691 patients
with anti-NMDAR encephalitis. Half of these atypical cases developed at least one
demyelinating episode separated in time from the episode of anti-NMDAR encephalitis,
making each disorder potentially recognizable on clinical grounds. However, the other half
of the patients developed concurrent symptoms and MRI findings of both disorders
confounding the diagnosis. These mixed phenotypes suggested the co-existence of two
simultaneously active immune mechanisms which was supported by the identification of
NMDAR and AQP4 or MOG antibodies in 7 of 11 cases.
The current data and a recent report indicating that patients with anti-NMDAR encephalitis
often have white matter changes visible with diffusion tensor imaging and resting functional
MRI, suggest that myelin disruption is more common than suspected on clinical grounds or
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by conventional MRI.21 The exact contribution of NMDAR antibodies and other immune
responses (AQP4, MOG, or yet unknown antibodies) to myelin dysfunction is unknown, but
it should be noted that oligodendrocytes contain NMDAR,22 and future studies will
determine whether they are affected by patients' antibodies. The role of MOG antibodies in
demyelinating disorders is unclear; these have been detected in pediatric patients with
monophasic or recurrent demyelination, but only rarely in classical MS. It has been
suggested that MOG antibodies could reflect an underlying pathogenic mechanism, a
secondary immune reaction, a bystander phenomenon, or even a beneficial effect.20
Only one of 23 patients with anti-NMDAR-encephalitis and atypical clinical and/or MRI
features had an ovarian teratoma, suggesting that patients with the nonparaneoplastic form
of the disorder are prone to autoimmunity. An example would be patient #3 who
sequentially developed three antibody-mediated disorders, including myasthenia gravis,
anti-AQP4 NMOSD, and anti-NMDAR encephalitis. Moreover, at least 4 of 691 patients
with NMDAR encephalitis had NMOSD with AQP4 antibodies, which is more than 200
times the expected frequency in the general population using an estimated prevalence of
anti-AQP4 NMO of 2.7/100,000 (p<0.0005).23 Despite this, clinical experience and
previous reports suggest that the association of anti-NMDAR encephalitis with other
autoimmune disorders occurs less frequently than in NMO/NMOSD where the association
with other autoimmune disorders has been reported in 30–75% of the patients.24
The clinical diagnosis of the patients reported here posed substantial difficulties. These
patients were often suspected to have ADEM, NMO or MS, but eventually the presence of
prominent psychiatric symptoms, orofacial dyskinesias, and/or autonomic dysfunction
suggested the diagnosis of anti-NMDAR encephalitis. We suspect that in similar cases the
diagnosis of anti-NMDAR encephalitis may not be considered, and these patients are
probably diagnosed and treated as having a demyelinating disorder.
In the current study, the episodes of anti-NMDAR encephalitis of most patients responded to
first-line therapies and resulted in mild residual deficits, but the episodes of demyelination
often required more intense immunotherapies and resulted in more deficits. This was
emphasized by the fact that during the demyelinating episodes the maximum symptom
severity was less compared with that of the episodes of anti-NMDAR encephalitis.
Moreover, the time lapsing between symptom onset and initiation of immunotherapy was
similar for the episodes of demyelination and the episodes of anti-NMDAR encephalitis. We
therefore postulate that different immune-mechanisms such as reversible antibody-mediated
effects on NMDAR,2,25 versus AQP4 complement-mediated toxicity26 or additional
cytotoxic T-cell effects on myelin, account for the different responses to treatment and
outcomes. Therefore, although the initial treatment approach with steroids is similar for anti-
NMDAR encephalitis and demyelinating disorders, subsequent treatments and prognosis are
different. An example is case 5 who developed mixed symptoms of anti-NMDAR
encephalitis along with more than 10 relapses of LETM and ON refractory to treatment.5
This patient was initially suspected to have seronegative NMO and treated as such, but
became asymptomatic after NMDAR antibodies were identified and treatment with
rituximab and cyclophosphamide was used. Moreover, the treatment plan for these disorders
is also different; for example, anti-NMDAR encephalitis often requires intensive care and
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rehabilitation addressed to the prominent psychiatric symptoms, executive dysfunction, and
challenging social interactions.27–29
This study has limitations related to the clinical history of some patients, which antedates the
availability of antibody-testing, and its retrospective nature. For example, patients with anti-
NMDAR encephalitis and previous DSE episodes without AQP4 were not examined during
the earlier DSE episodes for NMDAR antibodies. Therefore, the possibility that some of
these DSE episodes could represent atypical presentations of anti-NMDAR encephalitis
cannot be completely ruled out. We believe this is unlikely, because all these patients had
MOG antibodies which showed a significant correlation with DSE compared with the
control groups. On the other hand, the six patients with anti-NMDAR encephalitis and
AQP4-antibodies without DSE episodes (but with abnormal brain MRI in 5), have not
developed NMO as of the last follow-up (median 37 months, range 20–48 months); we
cannot exclude that these patients may develop NMO in the future.
The current findings indicate that patients with anti-NMDAR encephalitis may develop
demyelinating features as concurrent or independent episodes, and that patients with NMO
and other demyelinating disorders with unusual symptoms (e.g. prominent psychiatric
manifestations, orofacial dyskinesias, or autonomic instability among others) may have anti-
NMDAR encephalitis. Testing for AQP4 and MOG antibodies often help to recognize these
associations, but in rare instances no antibodies other than NMDAR are detected. Future
studies including prospective clinical assessment coupled with comprehensive antibody
testing will establish the actual frequency of these associations.
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Flow chart summarizing the patients included in the study
“NMDAR-DSE” or group 1 includes 5 patients with sequential episodes of anti-NMDAR
encephalitis and NMO or NMO spectrum disorder (NMOSD), and 7 patients with sequential
episodes of anti-NMDAR encephalitis and unusual symptoms and MRI findings suggesting
demyelination, but without criteria for NMO or NMOSD. The arrows indicate which of the
episodes occurred first, and the profile of antibodies associated with demyelination (AQP4,
MOG).
“NMDAR + clinical/MRI demyelination” or group 2, includes 11 patients in whom anti-
NMDAR encephalitis developed simultaneously with MRI and/or clinical features of
demyelination (8 of them with unusual symptoms for anti-NMDAR encephalitis).
Controls include three groups of patients with classical features of anti-NMDAR
encephalitis, NMO, or multiple sclerosis (relapsing-remitting [RRMS], secondary
progressive [SPMS], primary progressive [PPMS], clinically isolated syndrome [CIS]). All
136 patients were tested for NMDAR, NMO, and AQP4 antibodies and results are shown in
the chart.
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Demonstration of co-occurrence of NMDAR antibodies with aquaporin 4 (AQP4), or myelin
oligodendrocyte glycoprotein (MOG)
HEK293 cells transfected with the AQP4-M23 isoform (A), EGFP-N1-hMOG (B), and
GluN1/GluN2B subunits of the NMDAR (C); (A) serum from patient #1 (red) shows
reactivity with AQP4-M23 transfected HEK293 cells (green, commercial antibody against
AQP4; blue: DAPI; yellow: merged reactivities), in contrast, a control serum is negative. (B)
CSF from patient #6 (red) shows reactivity with MOG-EGFP transfected HEK293 cells
(green), in contrast, a control CSF is negative. (C) serum from patient #1 and CSF from
patient #6, also show reactivity with NR1/NR2B-transfected HEK293 cells (green,
commercial antibody against NR1 subunit), in contrast, a control CSF is negative. A–C:
magnification ×400, all bars = 10 micrometer.
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Clinical symptoms of the anti-NMDAR encephalitis episodes for the three groups of
patients.
(A) Comparison of the indicated groups of patients. §p = 0.031; ‡p = 0.002. The p-values are
uncorrected values.
(B) Clinical course and follow-up of antibodies in a patient with anti-NMDAR encephalitis
and DSE with MOG-antibodies.
MP methylprednisolone; PE plasma exchange; CTX cyclophosphamide
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Brain and spinal cord MRI of patients with anti-NMDAR encephalitis separated in time
from demyelinating episodes
(A–D) Patient 3 of table 1: Increased T2/FLAIR signal abnormalities involving the right
temporal lobe (A), caudate nucleus and frontal lobes (B), deterioration over time (C), and
near-resolution after treatment (D).
(E–J) patient 7: T2/FLAIR increased signal in the left parietal region during Sydenham's
chorea (E), subtle increase of the area of abnormal signal two weeks into the anti-NMDAR
encephalitis (F); new T2 lesions in the brainstem and Th9 and Th11–12 during the first
demyelinating episode (G–H); new T2/FLAIR abnormalities in the left facial collicular
region and cerebellum during the second demyelinating episode (I), and near-resolution
after treatment (J).
(K–P) patient 9: T2/FLAIR sequences showing no lesions during anti-NMDAR encephalitis
(K); several new lesions during the first demyelinating episode (L–M) and second
demyelinating episode (N). In the first demyelinating episode there was also involvement of
the spinal cord at Th6 (O–P).
(Q–T) patient 10: increased T2 signal (Q) and areas of contrast enhancement (R) during an
episode of demyelination. Different abnormalities, including increased T2 signal in cortical
frontal regions (S) without contrast enhancement (T) occurred during an episode of anti-
NMDAR encephalitis.
(U–X) patient 11: increased FLAIR signal in the cortex of the right hemisphere during anti-
NMDAR encephalitis (U); during a demyelinating episode with symptoms of optic neuritis,
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the right optic nerve shows increased T2 signal (V) with contrast enhancement (W), along
with enhancement in pre-chiasmal right and left optic nerves (X).
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Brain and spinal cord MRI of patients with anti-NMDAR encephalitis occurring
simultaneously with extensive, atypical FLAIR-T2 MRI-abnormalities
(A–B) Patient 17 of table 3, increased T2/FLAIR signal abnormalities involving the
periventricular, subcortical white matter (A), with hypointense T1 signals (B).
(C–D) Patient 13, increased FLAIR signal abnormalities in the pons, periventricular region
of the fourth ventricle (C), and the third ventricle (D).
(E–H) Patient 22, increased FLAIR signal abnormality in the left parietal region (E), with
ring-enhancement with Gadolinium at T1 (F); the abnormality improved after
immunotherapy (G), showing resolution of the gadolinium enhancement (H).
(I–L) Patient 19, increased FLAIR signal abnormalities, involving the brainstem (I),
subcortical white matter (J), and increased T2 signal in the spinal cord C3–C6 and Th3–Th4
(K), with gadolinium enhancement (L).
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Table 2
Main clinical features among the three groups of anti-NMDAR encephalitis patients
Group 1 NMDAR-DSE Group 2 NMDAR + clinicaland/or MRI-demyelination Group 3 NMDAR control p-value
*
AQP4 antibodies 4/12 5/11 1/50 (2%) < 0.0001
MOG antibodies 7/12 2/11 3/50 (6%) < 0.0001
Male 5/12 2/11 8/50 (16%) 0.18
Median age NMDAR IQR, range 30 (16.3–39.8; 14–55) 19 (13–37; 4–62) 20 (15.8–27.3; 1–46) 0.31
Median age DSE IQR, range 29.5 (13.5–37.8; 9–49) n.a. n.a. n.a. n.a.
Tumor 0/12 1/11 18/50 (36%) 0.011
mRS max (NMDAR)
      5 8/12 7/11 48/50 (96%) 0.001
      4 2/12 4/11 2/50 (4%)
      3 2/12 0/11 0/50 (0%)
Abnormal MRI 12/12 11/11 16/47 (34%) < 0.0001
  Infratentorial or spinal cord
abnormalities 8/12 5/11 1/47 (2%) < 0.0001
Abnormal EEG 8/9 8/10 41/47 (87%) 0.85
Abnormal CSF 9/12 10/11 40/46 (87%) 0.58
OCB 5/10 6/9 15/20 (75%) 0.40
DSE demyelinating syndrome episode; IQR interquartile range; mRS modified Rankin Scale; MRI magnetic resonance imaging; EEG
electroencephalography; CSF cerebrospinal fluid; OCB oligoclonal bands; n.a. not applicable
*
Median age was compared between groups using the Kruskal-Wallis test; for all other analyses we tested with the Fisher-Freeman-Halton
extension of the Fisher-Exact test.
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